The pathophysiology of CRS related to CAR-T cell therapy is associated with the activation and proliferation of CAR-T cells and release of high levels of several cytokines and chemokines including IFN-γ, IL-6, IL-8, IL-10, granulocyte macrophage colony-stimulating factor, and iNOS which in turn activate endogeneous myeloid cells (90–92). This evidence concerns the gene CSF2 and congenital rubella syndrome.